STANDARDISATION AND PHARMACOLOGICAL EVALUATION OF BRACLITAB SUSPENSION IN THE CHICK USING ANXIETY DEPRESSION MODEL Authors: Varsha G , SAI BALAJI O, FOUZIYA M, DINESH KUMAR, AUSAAF AHMED SIDDIQI, SUMITHRA M*
ABSTRACT
Introduction: Depressive disorder is a prevalent psychiatric disorder, which affects
3.5 % of the world’s population. The presently using drugs can impose a variety of side effects
including cardiac toxicity, hypokinesia, sexual dysfunction, body weight gain, and sleep
disorder. During the last decade, there is a growing interest in the therapeutic effects of natural
products on mental disorders. Tabernaemontana divaritica, Clitoria ternatea, and Centella
asiatica were investigated for antidepressant activity.
Methods: Braclitab suspension was prepared using the hydroalcoholic extract of
Tabernaemontana divaritica, Clitoria ternatea, and Centella asiatica and then subjected to
standardization followed by FTIR analysis to confirm herb-herb interaction. The antidepressant
activity was studied through stress induction in the chick model and hydroalcoholic extract of
was subjected to anti-depression activity in the chick model using stress vocalization and
glutathione reductase activity using the chick model.
Results: It has been observed from our study that vocalization study is reduced with the drug
administration and recent studies suggest that oxidative stress pathways may contribute to the
pathogenesis of depression by interacting with the monoamine reuptake process. It was
reported that individuals who suffer from depression displayed lower antioxidant potentials and
reduced brain GSH levels by glutathione reductase assay.
Conclusion: However further study is needed to understand the mechanism of action and to
identify the active component responsible for the antidepressant-like activity.
Keywords: Antidepressant Activity, GSH, Glutathione reductase, stress vocalization Publication date: 01/11/2023 https://ijbpas.com/pdf/2023/November/MS_IJBPAS_2023_7476.pdfDownload PDFhttps://doi.org/10.31032/IJBPAS/2023/12.11.7476